Hepion pharmaceuticals announces publication of data highlighting crv431’s potential as a treatment for chronic liver diseases
Hepion pharmaceuticals, inc. announced that the peer-reviewed journal of pharmacology and experimental therapeutics has published hepion’s research article entitled, “a pan-cyclophilin inhibitor, crv431, decreases fibrosis and tumor development in chronic liver disease models.” the study presents findings on crv431 that highlight its potential as a drug candidate for chronic liver diseases: in an in vitro cyclophilin isomerase assay, crv431 potently inhibited all cyclophilin isoforms tested, suggesting multiple disease mechanisms in the liver could be targeted. daily oral crv431 dosing in mice and rats, across a wide range of dosing levels, led to up to a 15-fold accumulation of crv431 in the liver compared to the blood, suggesting crv431’s pharmacokinetics favor hepatic delivery, which is optimal for the treatment of liver diseases. in a six-week carbon tetrachloride mouse model of fibrosis, crv431 significantly decreased liver fibrosis by 43% compared to control, whereas obeticholic acid — a compound in development as a nash treatment that was included as a comparator — had no statistically significant direct effect on fibrosis. three studies were conducted in a streptozotocin, high-fat diet mouse model of nash with crv431 doses of only 50 mg/kg administered orally each day. fibrosis significantly decreased by approximately 50%, compared to the control group. in a late-stage nash model where mice developed liver tumors, 10 weeks of oral crv431 treatment significantly decreased tumor burden (size and number of tumors) by about 50%.
HEPA Ratings Summary
HEPA Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission